Redefining the prognostic significance of RAS and BRAF V600E mutations on disease free survival in patients with colorectal cancer in the era of ct-DNA defined minimal residual disease: Results from the MD Anderson INTERCEPT Program.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Andrew Jared Pellatt, Giulia Maddalena, Madhulika Eluri, Christine Megerdichian Parseghian, Kathryn Aziz, Kristin Alfaro, Robert J. Kell, Alisha Heather Bent, Ryan W Huey, Abhineet Uppal, Tsuyoshi Konishi, Michael J. Overman, Maria Pia Morelli, Jason Willis, John Paul Y.C. Shen, Kanwal Pratap Singh Raghav, Timothy E. Newhook, Van K. Morris, Arvind Dasari, Scott Kopetz
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4391096713